By Mill Chart
Last update: Jan 22, 2024
Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ETON PHARMACEUTICALS INC (NASDAQ:ETON) is suited for growth investing. Investors should of course do their own research, but we spotted ETON PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.
Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.
ETON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 205 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ETON get a neutral evaluation. Nothing too spectacular is happening here. ETON is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
Check the latest full fundamental report of ETON for a complete fundamental analysis.
More growth stocks can be found in our Lois Navellier screen.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
ETON PHARMACEUTICALS INC
NASDAQ:ETON (4/26/2024, 7:00:02 PM)
3.45
+0.33 (+10.58%)
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is...
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the fourth quarter...
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growthFull...
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company...
Eton Pharmaceuticals (ETON) said Nitisinone capsules are now commercially available for the treatment of the ultra-rare disorder tyrosinemia type 1. Read more here.